Svetlana A Ivanova

List of Publications by Year
in descending order

149	1,891	279701 23	377752 34
papers	citations	h-index	g-index

172	172	172	1740
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	New insights into the mechanism of drug-induced dyskinesia. CNS Spectrums, 2013, 18, 15-20.	0.7	88
2	Use of Carnosine for Oxidative Stress Reduction in Different Pathologies. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-8.	1.9	87
3	The role of the habenula in the transition from reward to misery in substance use and mood disorders. Neuroscience and Biobehavioral Reviews, 2017, 80, 276-285.	2.9	71
4	Circuits regulating pleasure and happiness: the evolution of reward-seeking and misery-fleeing behavioral mechanisms in vertebrates. Frontiers in Neuroscience, 2015, 9, 394.	1.4	68
5	Circuits regulating pleasure and happiness in major depression. Medical Hypotheses, 2016, 87, 14-21.	0.8	56
6	Circuits Regulating Pleasure and Happinessâ€"Mechanisms of Depression. Frontiers in Human Neuroscience, 2016, 10, 571.	1.0	55
7	Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 475-481.	2.5	53
8	NMDA receptor genotypes associated with the vulnerability to develop dyskinesia. Translational Psychiatry, 2012, 2, e67-e67.	2.4	50
9	Signs of apoptosis of immunocompetent cells in patients with depression. Neuroscience and Behavioral Physiology, 2007, 37, 527-530.	0.2	44
10	Immune System Abnormalities in Schizophrenia: An Integrative View and Translational Perspectives. Frontiers in Psychiatry, 2022, 13, 880568.	1.3	43
11	Missense polymorphisms in three oxidativeâ€stress enzymes (GSTP1, SOD2, and GPX1) and dyskinesias in Russian psychiatric inpatients from Siberia. Human Psychopharmacology, 2010, 25, 84-91.	0.7	34
12	DNA-hydrolysing activity of IgG antibodies from the sera of patients with schizophrenia. Open Biology, 2015, 5, 150064.	1.5	34
13	Circuits regulating pleasure and happiness: evolution and role in mental disorders. Acta Neuropsychiatrica, 2018, 30, 29-42.	1.0	34
14	Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia. Heliyon, 2019, 5, e02033.	1.4	34
15	PIP5K2A-dependent regulation of excitatory amino acid transporter EAAT3. Psychopharmacology, 2009, 206, 429-435.	1.5	33
16	Circuits Regulating Pleasure and Happiness: The Evolution of the Amygdalar-Hippocampal-Habenular Connectivity in Vertebrates. Frontiers in Neuroscience, 2016, 10, 539.	1.4	31
17	Identification of 5-hydroxytryptamine receptor gene polymorphisms modulating hyperprolactinaemia in antipsychotic drug-treated patients with schizophrenia. World Journal of Biological Psychiatry, 2017, 18, 239-246.	1.3	28
18	Neurobiological mechanisms associated with antipsychotic drug-induced dystonia. Journal of Psychopharmacology, 2021, 35, 3-14.	2.0	28

#	Article	IF	Citations
19	The difference in serum proteomes in schizophrenia and bipolar disorder. BMC Genomics, 2019, 20, 535.	1.2	27
20	Association Between BDNF Gene Variant Rs6265 and the Severity of Depression in Antidepressant Treatment-Free Depressed Patients. Frontiers in Psychiatry, 2020, 11, 38.	1.3	27
21	Autoimmunity and immune system dysregulation in schizophrenia: IgGs from sera of patients hydrolyze myelin basic protein. Journal of Molecular Recognition, 2019, 32, e2759.	1.1	26
22	CYP1A2 and CYP2D6 Gene Polymorphisms in Schizophrenic Patients with Neuroleptic Drug-Induced Side Effects. Bulletin of Experimental Biology and Medicine, 2016, 160, 687-690.	0.3	25
23	Dried Blood Spot Analysis for Therapeutic Drug Monitoring of Clozapine. Journal of Clinical Psychiatry, 2017, 78, e1211-e1218.	1.1	25
24	Prolactin gene polymorphism (â˜' 1149 G/T) is associated with hyperprolactinemia in patients with schizophrenia treated with antipsychotics. Schizophrenia Research, 2017, 182, 110-114.	1.1	24
25	Association Study Indicates a Protective Role of Phosphatidylinositol-4-Phosphate-5-Kinase against Tardive Dyskinesia. International Journal of Neuropsychopharmacology, 2015, 18, pyu098-pyu098.	1.0	23
26	An association of AKT1 gene polymorphism with antidepressant treatment response. World Journal of Biological Psychiatry, 2016, 17, 239-242.	1.3	23
27	Cytochrome P450 1A2 co-determines neuroleptic load and may diminish tardive dyskinesia by increased inducibility. World Journal of Biological Psychiatry, 2015, 16, 200-205.	1.3	22
28	Circuits Regulating Pleasure and Happiness in Bipolar Disorder. Frontiers in Neural Circuits, 2017, 11, 35.	1.4	21
29	Evolution of circuits regulating pleasure and happiness with the habenula in control. CNS Spectrums, 2019, 24, 233-238.	0.7	19
30	Adipocytokines and Metabolic Syndrome in Patients with Schizophrenia. Metabolites, 2020, 10, 410.	1.3	19
31	Changes in Body Fat and Related Biochemical Parameters Associated With Atypical Antipsychotic Drug Treatment in Schizophrenia Patients With or Without Metabolic Syndrome. Frontiers in Psychiatry, 2019, 10, 803.	1.3	18
32	Putative role of pharmacogenetics to elucidate the mechanism of tardive dyskinesia in schizophrenia. Pharmacogenomics, 2019, 20, 1199-1223.	0.6	17
33	A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia. BMC Medical Genetics, 2019, 20, 47.	2.1	17
34	Serum BDNFâ€™s Role as a Biomarker for Motor Training in the Context of AR-Based Rehabilitation after Ischemic Stroke. Brain Sciences, 2020, 10, 623.	1.1	17
35	Exploring Brain Derived Neurotrophic Factor and Cell Adhesion Molecules as Biomarkers for the Transdiagnostic Symptom Anhedonia in Alcohol Use Disorder and Comorbid Depression. Frontiers in Psychiatry, 2020, 11, 296.	1.3	17
36	Study of Early Onset Schizophrenia: Associations of GRIN2A and GRIN2B Polymorphisms. Life, 2021, 11, 997.	1.1	17

#	Article	IF	Citations
37	Association study of genetic markers of schizophrenia and its cognitive endophenotypes. Russian Journal of Genetics, 2017, 53, 139-146.	0.2	15
38	Catalase activity of IgG antibodies from the sera of healthy donors and patients with schizophrenia. PLoS ONE, 2017, 12, e0183867.	1.1	15
39	Blood-Derived RNA- and microRNA-Hydrolyzing IgG Antibodies in Schizophrenia Patients. Biochemistry (Moscow), 2018, 83, 507-526.	0.7	15
40	Haplotype analysis of endothelial nitric oxide synthase (NOS3) genetic variants and metabolic syndrome in healthy subjects and schizophrenia patients. International Journal of Obesity, 2018, 42, 2036-2046.	1.6	15
41	Limited Associations Between 5-HT Receptor Gene Polymorphisms and Treatment Response in Antidepressant Treatment-Free Patients With Depression. Frontiers in Pharmacology, 2019, 10, 1462.	1.6	15
42	Cytokine Level Changes in Schizophrenia Patients with and without Metabolic Syndrome Treated with Atypical Antipsychotics. Pharmaceuticals, 2021, 14, 446.	1.7	15
43	Serum Glutathione in Patients with Schizophrenia in Dynamics of Antipsychotic Therapy. Bulletin of Experimental Biology and Medicine, 2015, 160, 283-285.	0.3	14
44	Likelihood of mechanistic roles for dopaminergic, serotonergic and glutamatergic receptors in tardive dyskinesia: A comparison of genetic variants in two independent patient populations. SAGE Open Medicine, 2016, 4, 205031211664367.	0.7	14
45	Hydrolysis by catalytic IgGs of microRNA specific for patients with schizophrenia. IUBMB Life, 2018, 70, 153-164.	1.5	14
46	The evolutionary old forebrain as site of action to develop new psychotropic drugs. Journal of Psychopharmacology, 2018, 32, 1277-1285.	2.0	14
47	Global hypomyelination of the brain white and gray matter in schizophrenia: quantitative imaging using macromolecular proton fraction. Translational Psychiatry, 2021, 11, 365.	2.4	14
48	Glucose-6-phosphate dehydrogenase and catalase activities in erythrocytes of schizophrenic patients under pharmacotherapy with traditional antipsychotics. Neurochemical Journal, 2014, 8, 66-70.	0.2	13
49	Association of Polymorphisms of Serotonin Transporter (5HTTLPR) and 5-HT2C Receptor Genes with Criminal Behavior in Russian Criminal Offenders. Neuropsychobiology, 2017, 75, 200-210.	0.9	13
50	The functional variant rs334558 of GSK3B is associated with remission in patients with depressive disorders. Pharmacogenomics and Personalized Medicine, 2018, Volume 11, 121-126.	0.4	13
51	Pharmacogenetics of tardive dyskinesia in schizophrenia: The role ofCHRM1andCHRM2muscarinic receptors. World Journal of Biological Psychiatry, 2020, 21, 72-77.	1.3	13
52	NRG1, PIP4K2A, and HTR2C as Potential Candidate Biomarker Genes for Several Clinical Subphenotypes of Depression and Bipolar Disorder. Frontiers in Genetics, 2020, 11, 936.	1.1	13
53	Association between 8 Pâ€glycoprotein (MDR1/ABCB1) gene polymorphisms and antipsychotic drugâ€induced hyperprolactinaemia. British Journal of Clinical Pharmacology, 2020, 86, 1827-1835.	1.1	13
54	Antioxidant and Immunotropic Properties of some Lithium Salts. Journal of Applied Pharmaceutical Science, 0, , 086-089.	0.7	13

#	Article	IF	Citations
55	Cortisol and DHEAS Related to Metabolic Syndrome in Patients with Schizophrenia . Neuropsychiatric Disease and Treatment, 2020, Volume 16, 1051-1058.	1.0	12
56	No involvement of the adenosine A2A receptor in tardive dyskinesia in Russian psychiatric inpatients from Siberia. Human Psychopharmacology, 2012, 27, 334-337.	0.7	11
57	Investigating the potential role of BDNF and PRL genotypes on antidepressant response in depression patients: A prospective inception cohort study in treatment-free patients. Journal of Affective Disorders, 2019, 259, 432-439.	2.0	11
58	Opening up new horizons for psychiatric genetics in the Russian Federation: moving toward a national consortium. Molecular Psychiatry, 2019, 24, 1099-1111.	4.1	11
59	Genetic Polymorphisms of 5-HT Receptors and Antipsychotic-Induced Metabolic Dysfunction in Patients with Schizophrenia. Journal of Personalized Medicine, 2021, 11, 181.	1.1	11
60	Polymorphisms of Catechol-O-Methyl Transferase (COMT) Gene in Vulnerability to Levodopa-Induced Dyskinesia. Journal of Pharmacy and Pharmaceutical Sciences, 2018, 21, 340-346.	0.9	10
61	Igg-Dependent Hydrolysis of Myelin Basic Protein of Patients with Different Courses of Schizophrenia. Journal of Immunology Research, 2020, 2020, 1-12.	0.9	10
62	IgG-Dependent Dismutation of Superoxide in Patients with Different Types of Multiple Sclerosis and Healthy Subjects. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-11.	1.9	10
63	Glutamate Concentration in the Serum of Patients with Schizophrenia. Procedia Chemistry, 2014, 10, 80-85.	0.7	9
64	Dehydroepiandrosterone sulphate as a putative protective factor against tardive dyskinesia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 50, 172-177.	2.5	9
65	Levodopa-Induced Dyskinesia Is Related to Indirect Pathway Medium Spiny Neuron Excitotoxicity: A Hypothesis Based on an Unexpected Finding. Parkinson's Disease, 2016, 2016, 1-5.	0.6	9
66	5-Hydroxytryptamine Receptors and Tardive Dyskinesia in Schizophrenia. Frontiers in Molecular Neuroscience, 2020, 13, 63.	1.4	9
67	Features of brain activity in alcohol dependence in the task of inhibitory control. Bulletin of Siberian Medicine, 2021, 19, 38-45.	0.1	9
68	Neurosteroids Dehydroepiandrosterone and Its Sulfate in Individuals with Personality Disorders Convicted of Serious Violent Crimes. Bulletin of Experimental Biology and Medicine, 2012, 154, 89-91.	0.3	8
69	Commentary on â€œA non-reward attractor theory of depressionâ€: A proposal to include the habenula connection. Neuroscience and Biobehavioral Reviews, 2017, 83, 736-741.	2.9	8
70	Body Fat Parameters, Glucose and Lipid Profiles, and Thyroid Hormone Levels in Schizophrenia Patients with or without Metabolic Syndrome. Diagnostics, 2020, 10, 683.	1.3	8
71	Circuits Regulating Pleasure and Happiness - Focus on Potential Biomarkers for Circuitry including the Habenuloid Complex. Acta Neuropsychiatrica, 2022, , 1-36.	1.0	8
72	Association of Cholinergic Muscarinic M4 Receptor Gene Polymorphism with Schizophrenia . The Application of Clinical Genetics, 2020, Volume 13, 97-105.	1.4	7

#	Article	IF	Citations
73	Amino Acid and Acylcarnitine Levels in Chronic Patients with Schizophrenia: A Preliminary Study. Metabolites, 2021, 11, 34.	1.3	7
74	Comparative Characteristics of the Metabolic Syndrome Prevalence in Patients With Schizophrenia in Three Western Siberia Psychiatric Hospitals. Frontiers in Psychiatry, 2021, 12, 661174.	1.3	7
75	Search for Possible Associations of FTO Gene Polymorphic Variants with Metabolic Syndrome, Obesity and Body Mass Index in Schizophrenia Patients. Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 1123-1131.	0.4	7
76	Circuits Regulating Pleasure and Happiness: A Focus on Addiction, Beyond the Ventral Striatum. , 0, , .		6
77	SIRT1 Allele Frequencies in Depressed Patients of European Descent in Russia. Frontiers in Genetics, 2018, 9, 686.	1.1	6
78	Therapeutic Drug Monitoring of Olanzapine and Cytochrome P450 Genotyping in Nonsmoking Subjects. Therapeutic Drug Monitoring, 2020, 42, 325-329.	1.0	6
79	Electroencephalographic Markers of Depressive Disorders Resistance to Pharmacotherapy and Determination of a Possible Approach to Individual Prognosis of Therapy Effectiveness. Psychiatry, 2021, 19, 39-45.	0.2	6
80	Beta-Endorphin and Oxytocin in Patients with Alcohol Use Disorder and Comorbid Depression. Journal of Clinical Medicine, 2021, 10, 5696.	1.0	6
81	No evidence so far of a major role of AKT1 and GSK3B in the pathogenesis of antipsychoticâ€induced tardive dyskinesia. Human Psychopharmacology, 2019, 34, e2685.	0.7	5
82	Clinical Evaluation of Different Treatment Strategies for Motor Recovery in Poststroke Rehabilitation during the First 90 Days. Journal of Clinical Medicine, 2021, 10, 3718.	1.0	5
83	Influence of eight ABCB1 polymorphisms on antidepressant response in a prospective cohort of treatmentâ€free Russian patients with moderate or severe depression: An explorative psychopharmacological study with naturalistic design. Human Psychopharmacology, 2021, , e2826.	0.7	5
84	Serum Cytokine Levels of Systemic Lupus Erythematosus Patients in the Presence of Concomitant Cardiovascular Diseases. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2022, 22, 852-861.	0.6	5
85	Catalytic Antibodies in Bipolar Disorder: Serum IgGs Hydrolyze Myelin Basic Protein. International Journal of Molecular Sciences, 2022, 23, 7397.	1.8	5
86	Circuits Regulating Pleasure and Happiness in Schizophrenia: The Neurobiological Mechanism of Delusions. , 2016, , .		4
87	Remaining Need for In Vitro Test to Elucidate 5-Hydroxytryptamine 2C Receptor Functioning. Journal of Clinical Psychopharmacology, 2018, 38, 410-411.	0.7	4
88	Blood-Serum Glutamate in Patients with Depressive Disorders as a Potential Peripheral Marker of the Prognosis of the Effectiveness of Therapy. Neurochemical Journal, 2018, 12, 366-372.	0.2	4
89	Consider Role of Glutamatergic Habenula-projecting Globus Pallidus in OCD. Pharmacopsychiatry, 2019, 52, 203-204.	1.7	4
90	Genetic polymorphisms of PIP5K2A and course of schizophrenia. BMC Medical Genetics, 2020, 21, 171.	2.1	4

#	Article	IF	Citations
91	Association of ANKK1 polymorphism with antipsychoticâ€induced hyperprolactinemia. Human Psychopharmacology, 2020, 35, e2737.	0.7	4
92	A genome-wide association study identifies a gene network associated with paranoid schizophrenia and antipsychotics-induced tardive dyskinesia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 105, 110134.	2.5	4
93	Preliminary Pharmacogenetic Study to Explore Putative Dopaminergic Mechanisms of Antidepressant Action. Journal of Personalized Medicine, 2021, 11, 731.	1.1	4
94	Morphophenotypic predictor of the development of visceral obesity in patients with schizophrenia receiving antipsychotic therapy. Bulletin of Siberian Medicine, 2018, 17, 54-64.	0.1	4
95	Đ¡ÑƒĐ¸Ñ†Đ¸Đ´Đ°Đ»ÑŒĐ½Đ¾Đµ Đ¿Đ¾Đ²ĐµĐ´ĐµĐ½Đ¸Đµ Đ±Đ¾Đ»ÑŒĐ½Ñ‹Ñ… Đ±Đ¸Đ¿Đ¾Đ»ÑÑ€Đ½Ñ‹Đ¼ Đ°Ñ„Ñ„ĐµĐºÑ‚Đ¸Đ²	0.1	4
96	Association of PIP4K2A Polymorphisms with Alcohol Use Disorder. Genes, 2021, 12, 1642.	1.0	4
97	Comparative efficiency of Proproten-100 during the therapy of patients with alcoholism in the stage of therapeutic remission. Bulletin of Experimental Biology and Medicine, 2003, 135/136, 171-175.	0.3	3
98	Spontaneous and In Vitro Induced Apoptosis of Lymphocytes and Neutrophils in Patients with Alcohol Dependence. Bulletin of Experimental Biology and Medicine, 2010, 149, 246-249.	0.3	3
99	The state of the antioxidant system during therapy of patients with multiple sclerosis. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, 2011, 5, 76-80.	0.2	3
100	Serum Levels of Neurosteroids in Patients with Affective Disorders. Bulletin of Experimental Biology and Medicine, 2015, 158, 638-640.	0.3	3
101	Peripheral Markers of Nervous Tissue Damage in Addictive and Affective Disorders. Neurochemical Journal, 2021, 15, 86-90.	0.2	3
102	Amino acids and acylcarnitines as potential metabolomic markers of schizophrenia: new approaches to diagnostics and therapy. Bulletin of Siberian Medicine, 2020, 18, 197-208.	0.1	3
103	Cognitive Changes in Comorbidity Alcohol Dependence and Affective Disorders. Psychiatry, 2020, 18, 42-48.	0.2	3
104	Glutamate Levelâ€™s in Blood Serum of Patients with Schisophrenic Spectrum and Bipolar Affective Disorder. Psychiatry, 2020, 18, 22-31.	0.2	3
105	Đ’Đ¾Đ·Đ¼Đ¾Đ¶Đ½Ñ‹Đµ Đ½ĐµĐ¹Ñ€Đ¾Ñ„Đ¸Đ·Đ¸Đ¾Đ»Đ¾Đ³Đ¸Ñ‡ĐµÑĐºĐ¸Đµ Đ¼Đ°Ñ€ĐºĐµÑ€Ñ‹ Đ´Đ»ÑĐ´Đ¸Ñ„Ñ„ĐµÑ€ĐµĐ½Ñ†	0.1	3
106	Changes in immunological parameters in patients with opium abuse receiving ANAR therapy. Bulletin of Experimental Biology and Medicine, 2003, 135/136, 189-191.	0.3	2
107	The correlation between schizophrenia duration and the serum concentration of dehydroepiandrosterone sulfate. Neurochemical Journal, 2011, 5, 290-293.	0.2	2
108	Effects of Neuroprotector Cortexin on the Dynamics of Neuroendocrine System Parameters in Patients with Organic Emotionally Labile (Asthenic) Disorders. Bulletin of Experimental Biology and Medicine, 2013, 155, 75-77.	0.3	2

#	Article	IF	Citations
109	Proteins of the Akt1/GSK-3Î² signaling pathway in peripheral blood mononuclear cells of patients with affective disorders. Neurochemical Journal, 2014, 8, 208-213.	0.2	2
110	Association of Polymorphic Variants of Brain-Derived Neurotrophic Factor Gene (Bdnf Rs6265) and Glutamate Transporter Gene of the Second Type (Slc1a2 Rs4354668) with the Course of Multiple Sclerosis in Patients Living in Tomsk Region. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, 2019, 74, 14-19.	0.2	2
111	A New Paradigm to Indicate Antidepressant Treatments. Pharmaceuticals, 2021, 14, 1288.	1.7	2
112	Gene Polymorphisms of Hormonal Regulators of Metabolism in Patients with Schizophrenia with Metabolic Syndrome. Genes, 2022, 13, 844.	1.0	2
113	Cytokine level in patients with mood disorder, alcohol use disorder and their comorbidity. World Journal of Biological Psychiatry, 2023, 24, 243-253.	1.3	2
114	Conformational Stability of Leukocyte Lactate Dehydrogenase in Healthy Men of Different Age. Bulletin of Experimental Biology and Medicine, 2012, 154, 44-46.	0.3	1
115	Effects of dehydroepiandrosterone sulfate on induced apoptosis of lymphocytes in healthy persons. Human Physiology, 2012, 38, 534-538.	0.1	1
116	Characteristics of membrane-bound pool of leukocyte lactate dehydrogenase in healthy men of different age. Human Physiology, 2015, 41, 444-447.	0.1	1
117	Association of drd3 gene polymorphisms with parkinson's disease (PD). Journal of the Neurological Sciences, 2015, 357, e253.	0.3	1
118	Cognitive impairment in patients after COVID-19. Ã‚kutskij Medicinskij Å¾urnal, 2021, , 69-72.	0.0	1
119	Clinical and laboratory assessment of the effectiveness of early rehabilitation of patients with stroke using assistive robotic tools. Bulletin of Siberian Medicine, 2020, 18, 55-62.	0.1	1
120	Rare single nucleotide variants in COL5A1 promoter do not play a major role in keratoconus susceptibility associated with rs1536482. BMC Ophthalmology, 2021, 21, 357.	0.6	1
121	Brain pathology in schizophrenia: association with clinical and constitutional factors. Ã‚kutskij Medicinskij Å¾urnal, 2019, , 17-21.	0.0	1
122	NEUROPHYSIOLOGICAL FEATURES OF PATIENTS WITH DIFFERENT RATES OF ALCOHOL DEPENDENCE DEVELOPMENT. Voprosy Narkologii, 2019, , 31-39.	0.1	1
123	Sexual differences in the clinical features of antipsychotic-induced hyperprolactinemia in patients with schizophrenia. Bulletin of Siberian Medicine, 2019, 18, 62-71.	0.1	1
124	Using the quantitative EEG method in predicting the response to treatment of affective disorders. V M Bekhterev Review of Psychiatry and Medical Psychology, 2020, , 26-32.	0.1	1
125	ÐœÐ¾ÐµÐ»ÑŒ Ð¿Ñ€Ð¾Ð³Ð½Ð¾Ð·Ð¸Ñ€Ð¾Ð²Ð°Ð½Ð¸Ñ•Ð¼ÐµÑ‚Ð°Ð±Ð¾Ð»Ð¸Ñ‡ÐµÑ•ÐºÐ¾Ð³Ð¾ ÑÐ¸Ð½Ð´Ñ€Ð¾Ð¼Ð° ÑƒÑ†		
126	Metabolic Syndrome in a Population of In-Patients with Schizophrenia in the Western Siberia. Psychiatry, 2021, 19, 52-60.	0.2	1

#	Article	IF	Citations
127	Genes of the Glutamatergic System and Tardive Dyskinesia in Patients with Schizophrenia. Diagnostics, 2022, 12, 1521.	1.3	1
128	The habenular volume and PDE7A allelic polymorphism in major depressive disorder: preliminary findings. World Journal of Biological Psychiatry, 2023, 24, 223-232.	1.3	1
129	P.2.016 Influence of atypical neuroleptic on cell apoptosis in patients with schizophrenia in the course of the therapy. European Neuropsychopharmacology, 2005, 15, S136-S137.	0.3	0
130	P.2.b.011 Antidepressant therapy and apoptosis of immnocompetent cells in patients with depressive disorders. European Neuropsychopharmacology, 2007, 17, S338.	0.3	0
131	Study of the indices of antioxidant defense in mental maladaptation. Human Physiology, 2012, 38, 543-547.	0.1	0
132	Correlation of concentrations of glutamate in serum samples and disability in multiple sclerosis. Journal of Neuroimmunology, 2014, 275, 130.	1.1	0
133	Antipsychotic-induced tardive dyskinesia: The role of glutamatergic system. European Psychiatry, 2016, 33, S97-S97.	0.1	0
134	Neurohumoral markers that predict the efficiency of pharmacologic therapy of depressive disorders. Neurochemical Journal, 2017, 11, 185-187.	0.2	0
135	IgG antibodies with nuclease activity in serum of patients with schizophrenia. European Neuropsychopharmacology, 2017, 27, S633-S634.	0.3	0
136	P.876 The effect of atypical antipsychotic therapy on hormonal and biochemical parameters in patients with schizophrenia. European Neuropsychopharmacology, 2019, 29, S583-S584.	0.3	0
137	P.390 Characteristics of metabolic hormones in patients with schizophrenia with antipsychotic-induced metabolic syndrome. European Neuropsychopharmacology, 2019, 29, S276-S277.	0.3	0
138	P.568 Trihexyphenidyl in combination with antipsychotic therapy does not affect the severity of neurocognitive deficits in patients with schizophrenia. European Neuropsychopharmacology, 2020, 40, S322-S323.	0.3	0
139	COMT gene polymorphism and antipsychotic- induced hyperprolactinemia in schizophrenia patients. , 2020, , .		0
140	Assessment of serum BDNF levels in complex rehabilitation of patients with ischemic stroke using traditional approaches to the restoration of motor functions. Bulletin of Siberian Medicine, 2021, 20, 38-45.	0.1	0
141	NFLUENCE OF PROPROTEN ON IMMUNE SYSTEM OF PATIENTS WITH ALCOHOLISM.. Alcoholism: Clinical and Experimental Research, 2004, 28, 32A.	1.4	0
142	Association of Ð¡ÐžÐœÐ¢ gene polymorphisms with Parkinsonâ€™s disease. Bulletin of Siberian Medicine, 2017, 16, 70-78.	0.1	0
143	Stress hormones in men whose professional activities are either office-based or of an extreme emergency nature. Ã‚kutskij Medicinskij Å¾urnal, 2019, , 20-22.	0.0	0
144	Ð¡ÑƒÐ¸Ð´Ð°Ð»ÑŒÐ½Ð¾Ðµ Ð¿Ð¾Ð²ÐµÐ´ÐµÐ½Ð¸Ðµ Ð±Ð¾Ð»ÑŒÐ½Ñ‹Ñ… Ñˆ Ð¸Ð·Ð¾Ñ„Ñ€ÐµÐ½Ð¸ÐµÐ¹ Ñ•Ð¼ÐµÑ‚Ð°Ð±Ð¾Ð		

#	Article	IF	Citations
145	Ð'Ð»Ð¸ÑÐ½Ð¸Ðµ ÐºÐ¾Ð³Ð½Ð¸Ñ‚Ð¸Ð²Ð½Ñ‹Ñ… Ñ„Ð°ÐºÑ‚Ð¾Ñ€Ð¾Ð² Ð½Ð° Ñ€ÐµÐ·ÑƒÐ»ÑŒÑ‚Ð°Ñ‚Ñ‹ Ð»ÐµÑ‡ÐµÐ½Ð¸Ñ		
146	Relationship of cognitive disorders with clinical features of alcohol dependence. Ã¸kutskij Medicinskij Å¾urnal, 2020, , 62-65.	0.0	0
147	Ð'Ð»Ð¸ÑÐ½Ð¸Ðµ Ð¾Ñ€Ð³Ð°Ð½Ð¸Ñ‡ÐµÑÐºÐ¾Ð³Ð¾ ÑÐ¾Ð»ÑŒÐ²ÐµÐ½Ñ‚Ð° Ð±ÐµÐ½Ð·Ð¸Ð½ Akt/m		
148	Molecular genetic study of clinical and cognitive features of schizophrenia: No associations with genes SOD2, GSTO1, NQO1. Sibirskij Å¾urnal KliniÄeskoj I Ã¨ksperimentalÊ¹noj Mediciny, 2022, 36, 99-106.	0.1	0
149	ÐžÑ†ÐµÐ½Ð°Ð° Ñ†Ð¸Ñ‚Ð¾Ñ‚Ð¾ÐºÑ‚Ð¸Ñ‡ÐµÑÐºÐ¾Ð³Ð¾ Ñ„Ñ„ÐµÐºÑ‚Ð° IgG, Ð²Ñ‹Ð´ÐµÐ»ÐµÐ½Ð½Ñ‹Ñ… Ð¿Ð¾Ñ‚Ð¾Ð¼ÐºÐ¾Ð² Ñ€		